Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal testosterone

K J McClellan1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|March 20, 1998
PubMed
Summary
This summary is machine-generated.

Nightly testosterone transdermal (TTD) system application normalizes hormone levels and improves sexual function in men with hypogonadism. This treatment is well-tolerated and maintains normal prostate health during long-term use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-grain scintillator screens for proton radiography.

The Review of scientific instruments·2024
Same author

Kondo quasiparticle dynamics observed by resonant inelastic x-ray scattering.

Nature communications·2022
Same author

Physics-informed machine learning for inorganic scintillator discovery.

The Journal of chemical physics·2018
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quantum critical fluctuations in the heavy fermion compound Ce(Ni0.935Pd0.065)₂Ge₂.

Journal of physics. Condensed matter : an Institute of Physics journal·2014
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Endocrinology
  • Men's Health
  • Pharmacology

Background:

  • Hypogonadism is characterized by insufficient testosterone production.
  • Current testosterone replacement therapies have limitations in mimicking natural circadian patterns.
  • Restoring physiological testosterone levels is crucial for male health and well-being.

Purpose of the Study:

  • To evaluate the efficacy and safety of a novel nightly testosterone transdermal (TTD) system in men with hypogonadism.
  • To assess the TTD system's ability to restore 24-hour serum testosterone profiles.
  • To determine the impact of TTD treatment on sexual function and hormonal parameters.

Main Methods:

  • A multicentre, open-label study involving men with hypogonadism.
  • Nightly application of the TTD system (5 mg/day) to nonscrotal skin sites.

Related Experiment Videos

  • Assessment of 24-hour serum testosterone, dihydrotestosterone, estradiol, and luteinizing hormone levels.
  • Evaluation of nocturnal erectile response, overall sexual function, and prostate parameters (PSA, prostate volume).

    • Main Results:

    • The TTD system successfully mimicked the circadian testosterone pattern in healthy men.
    • Normalized dihydrotestosterone/testosterone and estradiol/testosterone ratios were observed.
    • Luteinizing hormone levels decreased towards the normal range.
    • Significant improvements in nocturnal erectile response, sexual desire, arousal, activity frequency, orgasm, and satisfaction were noted over 12 months.
    • The TTD system was well-tolerated, with common application site reactions.
    • Prostate-specific antigen levels and prostate volume remained within normal limits during long-term treatment.

    Conclusions:

    • Nightly TTD system application is an effective treatment for hypogonadism, restoring physiological testosterone levels.
    • The TTD system significantly improves various aspects of sexual function in hypogonadal men.
    • The treatment demonstrates a favorable safety profile, including prostate health, during long-term use.